Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure por Navid Manouchehri, Victor H. Salinas, Negar Rabi Yeganeh, David Pitt, Rehana Z. Hussain, Olaf Stuve, Olaf Stuve

Ligazón do recurso

IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation. por Petra D Cravens, Rehana Z Hussain, William A Miller-Little, Li-Hong Ben, Benjamin M Segal, Emily Herndon, Olaf Stüve

Ligazón do recurso

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives por Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, Olaf Stuve

Ligazón do recurso

Clinical trials in multiple sclerosis: potential future trial designs por Navid Manouchehri, Yinan Zhang, Amber Salter, Rehana Z. Hussain, Hans-Peter Hartung, Bernhard Hemmer, Ralf Linker, Benjamin M. Segal, Gary Cutter, Olaf Stüve

Ligazón do recurso

Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design por Peter V. Sguigna, Rehana Z. Hussain, Annette Okai, Kyle M. Blackburn, Lauren Tardo, Mariam Madinawala, Julie Korich, Lori A. Lebson, Jeffrey Kaplan, Amber Salter, Navid Manouchehri, Olaf Stuve

Ligazón do recurso

MAdCAM-1-Mediated Intestinal Lymphocyte Homing Is Critical for the Development of Active Experimental Autoimmune Encephalomyelitis por Kristina Kuhbandner, Anna Hammer, Stefanie Haase, Elisa Terbrack, Alana Hoffmann, Angela Schippers, Norbert Wagner, Rehana Z. Hussain, William A. Miller-Little, Andrew Y. Koh, Joshua S. Stoolman, Benjamin M. Segal, Ralf A. Linker, Olaf Stüve, Olaf Stüve

Ligazón do recurso